Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib with Bevacizumab in Recurrent Glioblastoma
NCT04074785Phase 1Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Dec 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abemaciclib in glioblastoma (GBM) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Number of participants with adverse event. Started Dec 2019; status: terminated.
02
Drugs
abemaciclib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04074785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074785.